Brainstorm Cell Therapeutics (BCLI) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Brainstorm Cell Therapeutics (BCLIResearch Report) yesterday and set a price target of $8.00. The company’s shares opened today at $3.52.

McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Capricor Therapeutics, and VistaGen Therapeutics. According to TipRanks, McCarthy has an average return of -36.4% and a 19.32% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Brainstorm Cell Therapeutics with a $6.00 average price target.

See the top stocks recommended by analysts >>

BCLI market cap is currently $125.9M and has a P/E ratio of -5.41.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

Read More on BCLI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More